Validation of the German prostate-specific module

World Journal of Urology

Volumn 24, Issue 1, 2006, Pages 94-100

  Bestmann, Beate ^a   Rohde, Volker ^b   Siebmann, Jens Ulrich ^a   Galalae, Razvan ^a   Weidner, Wolfgang ^b   Küchler, Thomas ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Prostate cancer; Prostate specific module; Psychometric properties; Quality of life; Questionnaire; Validation

Indexed keywords

ADAPTIVE BEHAVIOR; AGE; AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; GERMANY; HUMAN; MALE; MEGAVOLTAGE RADIOTHERAPY; META ANALYSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROBABILITY; PROSTATE TUMOR; PROSTATECTOMY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INJURY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SICKNESS IMPACT PROFILE; VALIDATION STUDY;

ADAPTATION, PSYCHOLOGICAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COHORT STUDIES; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROBABILITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SICKNESS IMPACT PROFILE;

EID: 33644535454     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-005-0023-5     Document Type: Article

References (12)

1. Parker ME (1997) PSA thresholds for prostate cancer detection. JAMA 278(9):699-700
2. Tannock I (1995) Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies? Am J Med 99(6A):68S-69S
3. Biermann CW and Küchler T, "Lebensqualität in der urologischen Onkologie" in: Herbert Rübben (Hrg.): Uroonkologie; 3.ed., Springer 2001: 917-930
4. Sprangers MAG, Cull A, Bjordal K, Groenvold M, Aaronson NK for the EORTC STUDY GROUP ON QUALITY OF LIFE (EORTC-QOL). The European organization for research and treatment of cancer approach to the quality of life (QOL) assessment: Guidelines for developing questionnaire modules. Quality of Life Research 3:67-68, 1994
5. Biermann CW, Semjonow A, Hertle L, Küchler T Entwicklung eines prostata-spezifischen Moduls zu Messung von Lebensqualität nach radikaler Prostatektomie. Forum DKG Suppl. 75 (1997)
6. Fayers PM, Aaronson NK, Bjordal K, Curran D, and Groenvold M on behalf of the EORTC QUALITY OF LIFE STUDY GROUP. EORTC QLQ-C30 Scoring Manual: 2nd Edition" 1999, ISBN 2-930064-16-1, 78 pp
7. Aaronson NK, Ahmedzai S, Bergman B, et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
8. Staquet MJ, Fayers PM, Hays RD (eds) "Quality of life assessment in clinical trials: Methods and practice" Oxford Medical Publications (1998)
9. Riemer B "Lebensqualitätsmessung nach HDR-Brachytherapy und Teletherapie beim lokalisierten Prostatakarzinom" Univ. Diss., Kiel (1999)
10. Carmines EG, Zeller RA Reliability and validity assessment, Sage Publ. (1979)
11. Davis JW, Kuban DA, Lynch D, Schellhammer PF (2001) Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 166(3):947-952
12. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH (1998) The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure. Med Care 36:1002-1112